 November 2, 2023
Pharmacy Updates The MO HealthNet Pharmacy Program has been notified that brand name Flovent HFA® will be discontinued by the manufacturer. In response to this change in the marketplace and after consultation with several MO HealthNet providers, the following updates to the Corticosteroids, Oral Inhaled PDL Edit are effective 11/02/2023: - No change:
- Flovent HFA® will remain a preferred agent to allow current supply in the marketplace to be utilized.
- Fluticasone Propionate HFA (generic Flovent HFA®) will remain a non-preferred agent.
- New preferred DPI agents added to the PDL listing:
- Arnuity® Ellipta® (fluticasone furoate) is now a preferred agent.
- Asmanex® Twisthaler® (mometasone furoate) is now a preferred agent.
- MO HealthNet recognizes that pediatric patients may not have the ability to coordinate and generate the inspiratory flow rate necessary to effectively deliver the medication from a DPI. Therefore, participants < 12 years of age may access the following MDI agents as first line therapy without any pre-requisite trial of a preferred agent:
- Asmanex® HFA (mometasone furoate)
- Dulera® 50mcg/5mcg (mometasone furoate and formoterol fumarate dihydrate)
Please reference the full criteria at Corticosteroids-Oral-Inhaled-New.pdf (mo.gov). MO HealthNet continues to recommend the use of SMART therapy for all appropriate participants with asthma. Symbicort® and Dulera® 100mcg/5mcg continue to remain preferred agents with no prior authorization required. More information on SMART therapy may be accessed here: MO HealthNet Asthma SMART Flyer (8.5 x 11 in). Providers with questions may call MO HealthNet at 800-392-8030. .
Contact Us | 
No comments:
Post a Comment
Keep a civil tongue.